# MB-dNPM1-TCR.1 in Relapsed/Refractory AML

> **NCT06424340** · PHASE1,PHASE2 · RECRUITING · sponsor: **Miltenyi Biomedicine GmbH** · enrollment: 29 (estimated)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **BIOLOGICAL:** MB-dNPM1-TCR.1

## Key facts

- **NCT ID:** NCT06424340
- **Lead sponsor:** Miltenyi Biomedicine GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2028-06
- **Final completion:** 2028-06
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06424340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06424340, "MB-dNPM1-TCR.1 in Relapsed/Refractory AML". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06424340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*